US EditionNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
- Neurocrine Biosciences published a post-hoc analysis of INGREZZA studies in older adults with tardive dyskinesia on April 24, 2025.
- Older adults face higher risk for tardive dyskinesia, a movement disorder affecting at least 800,000 US adults.
- The analysis included 304 participants from two 48-week studies, with 55 participants aged 65 and older receiving INGREZZA.
- Chief Medical Officer Eiry W. Roberts stated these data show "sustained improvement up to 48 weeks" for older participants.
- The analysis demonstrated INGREZZA's long-term efficacy and safety profile remained consistent for adults aged 65 and older.
Insights by Ground AI
Does this summary seem wrong?
28 Articles
28 Articles
All
Left
4
Center
13
Right
Napa Valley Register+27 Reposted by 27 other sources
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern
Coverage Details
Total News Sources28
Leaning Left4Leaning Right0Center13Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
L 24%
C 76%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage